GE, Nissan offer $7.9M for $2.5M COVID-19 vaccine, rebate program
GE announced Wednesday that it has offered to pay $2,5 million to the states of New York, Connecticut, Massachusetts, and Rhode Island to purchase the COVID vaccine for residents of the five most populous U.S. states.
GE’s new offer includes $2 million for each state that offers COVID vaccines, and $2 billion in federal funding, which could allow states to purchase vaccines from GE for $1.9 billion.
The federal rebate program will not apply to COVID treatments purchased outside of the U.s.
The program is expected to generate at least $300 million in federal revenue for states and could generate more than $700 million in total.
The program, called the COVAIL COVID Initiative, was approved by the U,S.
Food and Drug Administration on May 17, 2017, and approved by Congress in April.
In 2018, GE announced it would also offer COVID vaccinations to the public in 20 states.
In September, the Centers for Disease Control and Prevention reported that there had been 3,955 COVID infections in the U in 2017.
The outbreak is the highest since 2009, when there were more than 1,600 COVID deaths.
More: The federal government will spend $30.5 million this year to cover COVID costs, according to a September announcement.
The program, the government said, “will be administered by the Centers For Disease Control (CDC) and states through the Office of the National Coordinator for the Prevention of Infectious Diseases (ONCID), as part of a partnership between GE, the American Heart Association, and the National Institutes of Health (NIH).
More information about the federal COVAILL COVID Program: http://www.gov/fda/publications/covaccine/programs/new-swamp-gov.htm#.
U1s0hX8QH4sIn a statement, GE said it “looks forward to continuing its partnership with ONCID and the CDC, which will continue to deliver COVID prevention vaccines to the U.”
Last month, GE was the first U.K. multinational to offer a COVID treatment to its U.k. customers. “
We believe this partnership will help make COVID a manageable and manageable disease in our markets and provide our customers with greater choice in COVID vaccination options,” the company said.
Last month, GE was the first U.K. multinational to offer a COVID treatment to its U.k. customers.
The company said Wednesday that a second trial of the vaccine, which is still in early stages, has been approved for sale in the United Kingdom.
While GE said Wednesday it will offer the vaccine to the United States, it did not specify when it might start offering it in other markets.
On Thursday, the company will also offer a new COVID drug, called COVIDA-T, in Europe, in the coming weeks, which would be the first vaccine from a major pharmaceutical company that would also be made available to the general public.